Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin’s lymphoma (NHL). A multi- center trial by the Austrian Working Group For Medical Tumor Therapy

[1]  H. Hausmaninger,et al.  CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Murata,et al.  Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non‐Hodgkin's lymphoma , 1994, Cancer.

[3]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[4]  B. Coiffier,et al.  Possible toxicity with the association of G-CSF and bleomycin , 1994, The Lancet.

[5]  M. Engelhard,et al.  Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas [see comments] , 1993 .

[6]  T M Grogan,et al.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[7]  J. von Pawel,et al.  Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. , 1993, European journal of cancer.

[8]  M. Engelhard,et al.  Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. , 1993, Blood.

[9]  M. Shipp.  Prognostic factors in non-Hodgkin's lymphoma. , 1992, Current opinion in oncology.

[10]  J. Radford,et al.  Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. , 1992, Blood.

[11]  M. Kris,et al.  Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer , 1991 .

[12]  E. Jaffe,et al.  Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  W. Hryniuk,et al.  The calculation of received dose intensity. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  G. Pinkus,et al.  The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R Storb,et al.  Effect of recombinant human granulocyte colony-stimulating factor on hematopoiesis of normal dogs and on hematopoietic recovery after otherwise lethal total body irradiation. , 1989, Blood.

[16]  B. Coiffier,et al.  LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Green,et al.  EFFECT OF GRANULOCYTE COLONY STIMULATING FACTOR ON NEUTROPENIA INDUCED BY CYTOTOXIC CHEMOTHERAPY , 1988, The Lancet.

[18]  E. Gehan,et al.  Reporting outcomes in Hodgkin's disease and lymphoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  K. Zsebo,et al.  In vivo stimulation of granulopoiesis by recombinant human granulocyte colony-stimulating factor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Gabrilove,et al.  Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. , 1986, Science.

[21]  J. Connors,et al.  MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. , 1985, Annals of internal medicine.

[22]  Prof. Dr. Dr. h.c. mult. Karl Lennert,et al.  Histopathologie der Non-Hodgkin-Lymphome , 1981, Springer Berlin Heidelberg.

[23]  M Tubiana,et al.  Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.

[24]  Y. S. Sathe,et al.  Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. , 1966, Annals of internal medicine.